Anti-apoptotic Proteolysis Targeted Chimeras (PROTACs) in Cancer Therapy
Main Article Content
Abstract
Targeted protein degradation is an emerging approach for novel drug discovery and basic research. Several degrader molecules have been developed including PROteolysis-TArgeting Chimeras (PROTACs), specific and nongenetic Inhibitor of APoptosis protein (IAP)-dependent Protein ERasers (SNIPERs), IAP antagonists, deubiquitylase inhibitors, hydrophobic tagging molecules, and E3 modulators. The chimeric degrader molecules PROTACs and SNIPERs are made of linking a target protein-ligand to an E3 ubiquitin ligase binding ligand. This modular nature of these chimeric molecules supports versatile protein targets by substituting target ligands. They induce ubiquitylation and proteasomal degradation of the target protein in the cytosol via recruiting an E3 ubiquitin ligase to the target protein. The bridging of the target protein and the E3 ubiquitin ligase facilitates ubiquitylation of the protein and its proteasomal degradation. PROTACs chimeric molecules recruit von Hippel–Lindau or cereblon ubiquitin ligases, while SNIPERs induce simultaneous degradation of cIAP1/2 or XIAP together with the target proteins. Several B-cell Lymphoma 2 (BCL-2) family anti-apoptosis proteins BCL-2, BCL-XL, and MCL-1 are validated anticancer targets and are upregulated in various malignancies. Also, aberrant expression of cIAP1/2 and XIAP with a concomitant increase in apoptosis resistance has been reported. The dysregulation of BCL2 and IAP gene expression in cancer disease is mainly caused by upregulation of the bromodomain and extra-terminal domain (BET) proteins. Degradation of the cellular anti-apoptosis proteins mentioned is a promising approach to induce apoptosis in tumor cells and overcome treatment resistance. Various types of protein degradation strategies have been developed and used. This article overviewed various chimeric compounds capable of inducing the degradation of anti-apoptosis proteins BCL2, BET, and IAP in cancer treatment.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Lee, Y. T., Tan, Y. J. & Oon, C. E. Molecular targeted therapy: Treating cancer with specificity. European journal of pharmacology 834, 188–196 (2018).
3. Shawver, L. K., Slamon, D. & Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer cell 1, 117–123 (2002).
4. Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Science translational medicine 9, eaag1166 (2017).
5. Zhao, L., Zhao, J., Zhong, K., Tong, A. & Jia, D. Targeted protein degradation: mechanisms, strategies and application. Signal transduction and targeted therapy 7, 113 (2022).
6. Li, R. et al. Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future. Molecules 27, 8828 (2022).
7. Yim, W. W.-Y. & Mizushima, N. Lysosome biology in autophagy. Cell discovery 6, 6 (2020).
8. Zengerle, M., Chan, K.-H. & Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS chemical biology 10, 1770–1777 (2015).
9. Wang, S., He, F., Tian, C. & Sun, A. From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation. Pharmaceuticals 17, 100 (2024).
10. Naito, M., Ohoka, N. & Shibata, N. SNIPERs—Hijacking IAP activity to induce protein degradation. Drug Discovery Today: Technologies 31, 35–42 (2019).
11. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nature methods 6, 917–922 (2009).
12. Buckley, D. L. & Crews, C. M. Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System. Angewandte Chemie International Edition 53, 2312–2330 (2014).
13. Ohoka, N. et al. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation. Journal of Biological Chemistry 293, 6776–6790 (2018).
14. Liu, J. et al. PROTACs: a novel strategy for cancer therapy. in Seminars in Cancer Biology vol. 67 171–179 (Elsevier, 2020).
15. Ito, T. Protein degraders-from thalidomide to new PROTACs. The Journal of Biochemistry mvad113 (2023).
16. Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature reviews Molecular cell biology 20, 175–193 (2019).
17. Ke, F. F. et al. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. Cell 173, 1217–1230 (2018).
18. Hanahan, D. Hallmarks of cancer: new dimensions. Cancer discovery 12, 31–46 (2022).
19. Yap, J. L., Chen, L., Lanning, M. E. & Fletcher, S. Expanding the cancer arsenal with targeted therapies: Disarmament of the antiapoptotic Bcl-2 proteins by small molecules: Miniperspective. Journal of Medicinal Chemistry 60, 821–838 (2017).
20. Brahmbhatt, H., Oppermann, S., Osterlund, E. J., Leber, B. & Andrews, D. W. Molecular pathways: leveraging the BCL-2 interactome to kill cancer cells—mitochondrial outer membrane permeabilization and beyond. Clinical Cancer Research 21, 2671–2676 (2015).
21. Lopez, A. et al. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nature communications 13, 1199 (2022).
22. Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477–482 (2016).
23. Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death & Differentiation 25, 65–80 (2018).
24. Mitchell, K. O. et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer research 60, 6318–6325 (2000).
25. Grossmann, M. et al. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. The EMBO journal 19, 6351–6360 (2000).
26. Roe, J.-S., Mercan, F., Rivera, K., Pappin, D. J. & Vakoc, C. R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Molecular cell 58, 1028–1039 (2015).
27. Wang, N., Wu, R., Tang, D. & Kang, R. The BET family in immunity and disease. Signal transduction and targeted therapy 6, 23 (2021).
28. Yang, H., Wei, L., Xun, Y., Yang, A. & You, H. BRD4: An emerging prospective therapeutic target in glioma. Molecular Therapy-Oncolytics 21, 1–14 (2021).
29. Silke, J. & Meier, P. Inhibitor of apoptosis (IAP) proteins–modulators of cell death and inflammation. Cold Spring Harbor perspectives in biology 5, a008730 (2013).
30. Vogler, M. Targeting BCL2-proteins for the treatment of solid tumours. Advances in medicine 2014, (2014).
31. Ngoi, N. Y. L. et al. Targeting mitochondrial apoptosis to overcome treatment resistance in cancer. Cancers 12, 574 (2020).
32. Hantusch, A., Rehm, M. & Brunner, T. Counting on Death–Quantitative aspects of Bcl-2 family regulation. The FEBS Journal 285, 4124–4138 (2018).
33. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine 19, 202–208 (2013).
34. Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science translational medicine 7, 279ra40-279ra40 (2015).
35. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer research 68, 3421–3428 (2008).
36. Deeks, E. D. Venetoclax: first global approval. Drugs 76, 979–987 (2016).
37. Kaefer, A. et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer chemotherapy and pharmacology 74, 593–602 (2014).
38. He, Y. et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol 13, 95 (2020).
39. Jia, Y. et al. Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells. Blood 140, 3347–3349 (2022).
40. Khan, S. et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol 15, 23 (2022).
41. Thummuri, D. et al. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther 21, 184–192 (2022).
42. Xu, Y., Lei, Z., Zhu, J. & Wan, L. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun 623, 120–126 (2022).
43. Shebl, B. et al. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight 7, e161820 (2022).
44. Zhang, X. et al. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem 192, 112186 (2020).
45. Kolb, R. et al. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun 12, 1281 (2021).
46. Jaiswal, A. et al. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis. Cancer Chemother Pharmacol 91, 89–95 (2023).
47. Zhang, X. et al. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun (Camb) 55, 14765–14768 (2019).
48. Chung, C. et al. Structural insights into PROTAC-mediated degradation of Bcl-xL. ACS Chemical Biology 15, 2316–2323 (2020).
49. Shi, C. et al. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis. Cell Death Dis 10, 815 (2019).
50. Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
51. Bai, L. et al. Targeted degradation of BET proteins in triple-negative breast CancerSmall-molecule degraders of BET proteins in TNBC. Cancer research 77, 2476–2487 (2017).
52. Noblejas-López, M. D. M. et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J Exp Clin Cancer Res 38, 383 (2019).
53. Qin, C. et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. Journal of medicinal chemistry 61, 6685–6704 (2018).
54. Cho, H., Jeon, S. I., Shim, M. K., Ahn, C.-H. & Kim, K. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy. Biomaterials 295, 122038 (2023).
55. Qin, A.-C. et al. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis 11, 805 (2020).
56. He, Y. et al. Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles. Mater Today Bio 16, 100423 (2022).
57. Zhang, H. et al. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells. Front Oncol 9, 1471 (2019).
58. He, L., Chen, C., Gao, G., Xu, K. & Ma, Z. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma. Aging (Albany NY) 12, 4547–4557 (2020).
59. Sun, B. et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia 32, 343–352 (2018).
60. Saenz, D. T. et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia 31, 1951–1961 (2017).
61. Saraswat, A. et al. Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer. Nanomedicine (Lond) 15, 1761–1777 (2020).
62. Lu, J. et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol 22, 755–763 (2015).
63. Noblejas-López, M. D. M. et al. MZ1 co-operates with trastuzumab in HER2 positive breast cancer. J Exp Clin Cancer Res 40, 106 (2021).
64. Mill, C. P. et al. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134, 59–73 (2019).
65. Hu, R. et al. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. Eur J Med Chem 227, 113922 (2022).
66. Tong, J. et al. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. Oncogene 40, 6566–6578 (2021).
67. Ma, L. et al. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. Cancer Biol Ther 23, 1–15 (2022).
68. Zhang, K. et al. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathol Oncol Res 28, 1610447 (2022).
69. Wang, Q. et al. Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells. Front Chem 11, 1121724 (2023).
70. Liao, X. et al. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways. Front Oncol 11, 753119 (2021).
71. Gollavilli, P. N. et al. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. Cancer Res 78, 4760–4773 (2018).
72. Deng, Y. et al. ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. Front Pharmacol 13, 858901 (2022).
73. Zhang, X. et al. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma. Biochem Biophys Res Commun 604, 63–69 (2022).
74. Jia, S.-Q. et al. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma. J Immunol Res 2022, 7945884 (2022).
75. Wu, S. et al. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting ‘Undruggable’ Myc-pathway genes. Cancer Cell Int 21, 230 (2021).
76. Fiskus, W. et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 35, 2621–2634 (2021).
77. He, Y. et al. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. J Control Release 354, 155–166 (2023).
78. Zhang, X. et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32, 2224–2239 (2018).
79. Lu, Q. et al. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells. Am J Transl Res 11, 5728–5739 (2019).
80. Rathod, D., Fu, Y. & Patel, K. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation. Eur J Pharm Sci 138, 105039 (2019).
81. Zoppi, V. et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7. Journal of medicinal chemistry 62, 699–726 (2018).
82. Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angewandte Chemie International Edition 56, 5738–5743 (2017).
83. Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences 113, 7124–7129 (2016).
84. Park, S. et al. Discovery of pan-IAP degraders via a CRBN recruiting mechanism. Eur J Med Chem 245, 114910 (2023).
85. Baker, I. M., Smalley, J. P., Sabat, K. A., Hodgkinson, J. T. & Cowley, S. M. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs). Biochemistry 62, 645–656 (2023).
86. Ng, Y. L. D. et al. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins. J Med Chem 66, 4703–4733 (2023).
87. Zhang, X. et al. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem 199, 112397 (2020).
88. Steinebach, C. et al. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci 11, 3474–3486 (2020).
89. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
90. Ocaña, A., Nieto-Jiménez, C. & Pandiella, A. BET inhibitors as novel therapeutic agents in breast cancer. Oncotarget 8, 71285 (2017).
91. Naito, M. Targeted protein degradation and drug discovery. J Biochem 172, 61–69 (2022).
92. Ohoka, N. et al. Different degradation mechanisms of inhibitor of apoptosis proteins (IAPs) by the specific and nongenetic IAP-dependent protein eraser (SNIPER). Chemical and Pharmaceutical Bulletin 67, 203–209 (2019).
93. Feltham, R. et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. Journal of Biological Chemistry 286, 17015–17028 (2011).
94. Lalaoui, N. et al. Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics. Cancer cell 29, 145–158 (2016).
95. Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nature reviews Drug discovery 18, 949–963 (2019).
96. Ocaña, A. & Pandiella, A. Proteolysis targeting chimeras (PROTACs) in cancer therapy. Journal of Experimental & Clinical Cancer Research 39, 189 (2020).
97. Shao, J. et al. Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O’PROTAC): effective targeting of LEF1 and ERG. Advanced Science 8, 2102555 (2021).
98. Ohoka, N., Misawa, T., Kurihara, M., Demizu, Y. & Naito, M. Development of a peptide-based inducer of protein degradation targeting NOTCH1. Bioorganic & medicinal chemistry letters 27, 4985–4988 (2017).
99. Zeng, S. et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. European Journal of Medicinal Chemistry 210, 112981 (2021).
100. Hanzl, A. & Winter, G. E. Targeted protein degradation: current and future challenges. Current opinion in chemical biology 56, 35–41 (2020).
101. Bellmann, L., Klein, R. & Rarey, M. Calculating and Optimizing Physicochemical Property Distributions of Large Combinatorial Fragment Spaces. Journal of Chemical Information and Modeling 62, 2800–2810 (2022).
102. J Kenten, S Roberts 1999 Controlling protein levels in eucaryotic organisms US Patent US6306663B1.
103. Home | ClinicalTrials.gov. https://clinicaltrials.gov/.
104. Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj 372, (2021).